 Subjects who successfully qualify will be randomized at Baseline Visit 2 to their assigned medication CF101 or matching placebo to be taken orally every 12 hours for 16 weeks. Subjects will return for assessments and a new supply of study medication at Weeks 2, 4, 8, 12, and for final assessment and discharge at Week 16. A safety telephone call will be made at Week 18. 